Creo Medical Group has received its first commercial orders for its Speedboat device from two hospitals in the US.
According to the company, Speedboat is the first in a range of gastrointestinal (GI) devices to be cleared for use with the Croma Advanced Energy platform.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The platform combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for coagulation and tissue ablation.
Creo Medical Group CEO Craig Gulliford said: “Initial revenues from the first device this year is once again in-line with expectations and combined with the clearance and launch of a suite of further GI devices in the coming year, we are on-track for scaling up the commercial launch of a suite of game changing GI products.
“We are all really focused on extending this impact with more physicians trained and with more products launched over the coming months.”
The purchase orders follow the successful launch of Creo Medical’s Clinical Education Programme in the US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThey are a follow-on order of the disposable Speedboat devices following the initial sales of products for training purposes.
Creo Medical noted that these first commercial sales represent a key milestone for the company as it launches the full range of products for the CROMA platform.
GI Endoscopists in the UK, South Africa, Mainland Europe and the US have used the company’s Speedboat device to perform multiple successful treatments, removing lesions in upper as well as lower GI cases. It is designed to reduce the risks associated with alternative open, laparoscopic and existing endoscopic procedures as well as reduce extended hospital stays.
